ADVANCES IN WHICH
UCSF CARDIOVASCULAR RESEARCH INSTITUTE
HAS PLAYED A MAJOR ROLE
|
1958
Catheterization for diagnosis of congenital cardiac anomalies.
Revolutionized diagnosis and treatment of congenital heart disease.
|
 |
|
1961-1972
Pulmonary surfactant.
Discovered, characterized, and developed as therapy for respiratory distress syndrome in premature infants. Decreased overall infant mortality.
|
 |
|
1976
Indomethacin for patent ductus arteriosus closure.
Allows infants with this congenital abnormality to avoid major surgery.
|
|
|
1981
Catheter-based ablation therapy for cardiac arrhythmias.
Cures some types of heart-rhythm problems without need for open-heart surgery.
|
|
|
1976-80
Role of diastolic dysfunction in heart failure.
Improved understanding and treatment of heart failure.
|
|
|
1987
ACE inhibitors in heart failure.
Contributed to this application of ACE inhibitors, which improve and extend lives of heart-failure patients.
|
|
|
1988-1998
Eptifibatide.
Used in approximately one million patients each year to prevent clotting during angioplasty and interrupt developing heart attacks.
|
|
|
1991
Identification of thrombin receptor.
Enabled development of new and potentially revolutionary class of clot-preventing drugs now in clinical trials.
|
|
|
1992
Identification of VEGF receptor.
Enabled development of Avastin and other inhibitors of tumor blood vessel growth. .
|
|
|
1994
Identification of monocyte chemoattractant protein receptor.
Enabled development of new class of anti-inflammatory drugs now in clinical trials.
|
|
|
1995
Catheter-based aortic aneurysm repair and other surgical innovations.
Allows some patients to avoid major surgery and allows repairs not previously possible.
|
|
|
1997
Roles of IgE and inflammation in asthma; proof of concept for Xolair.
Key steps in developing new class of asthma drug.
|
|
|
2001
Low tidal volume ventilation in adult respiratory distress syndrome.
Decreases mortality in patients with respiratory distress syndrome.
|
|
|
2002
Roles of collectins in host defense.
May enable development of new class of antimicrobial agents.
|
|
|
2000-2006
High throughput genotyping (HapMap).
Enabled new level of genetic research that will lead to tailoring measures to prevent heart attacks to a patient’s particular risk factors and more precise prevention, diagnosis, and treatment of heart-rhythm problems.
|
 |
|
